Preferential sensitivity to HDAC inhibitors in tumors with CREBBP mutation
Crossref DOI link: https://doi.org/10.1038/s41417-019-0099-5
Published Online: 2019-05-09
Published Print: 2020-05
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Hellwig, Malte
Merk, Daniel J.
Lutz, Beat
Schüller, Ulrich http://orcid.org/0000-0002-8731-1121
Text and Data Mining valid from 2019-05-09
Version of Record valid from 2019-05-09
Article History
Received: 28 March 2019
Accepted: 27 April 2019
First Online: 9 May 2019
Compliance with ethical standards
:
: The authors declare that they have no conflict of interest.